Morishita JintanMORISHITA JINTAN CO.,LTD.4524東証スタンダード医薬品FY ending Mar 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥5 is left as operating profit. Revenue changed -0.6% from the prior year, operating profit -13.9%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 3.0% | 0.66× | 2.0% | 1.57× | 3.1% |
| 2023 | 4.3% | 0.74× | 3.2% | 1.63× | 5.2% |
| 2024 | 5.6% | 0.75× | 4.2% | 1.69× | 7.1% |
| 2025 | 4.3% | 0.73× | 3.1% | 1.71× | 5.3% |
| 2026 | 4.9% | 0.69× | 3.4% | 1.71× | 5.9% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 9,563 | 11,359 | 12,406 | 12,766 | 12,688 |
| Cost of revenue | 4,686 | 6,047 | 6,408 | 6,793 | 6,594 |
| Gross profit | 4,876 | 5,311 | 5,997 | 5,973 | 6,094 |
| SG&A | 4,577 | 4,742 | 5,281 | 5,169 | 5,402 |
| Operating income | 299 | 569 | 716 | 804 | 692 |
| Pretax income | 385 | 623 | 820 | 772 | 773 |
| Income tax | 101 | 131 | 123 | 225 | 144 |
| Net income attributable to owners | 283 | 491 | 697 | 547 | 628 |
| Operating margin | 3.1% | 5.0% | 5.8% | 6.3% | 5.5% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥2.14B | ¥2.41B | ¥1.09B | ¥1.94B | ¥1.83B |
| Total assets | ¥14.5B | ¥16.1B | ¥17.2B | ¥17.9B | ¥18.6B |
| Net assets | ¥10.5B | ¥11.4B | ¥12.1B | ¥12.2B | ¥13B |
| Share capital | ¥3.54B | ¥3.54B | ¥3.54B | ¥3.54B | ¥3.54B |
| Property, plant and equipment | ¥4.47B | ¥4.46B | ¥5.39B | ¥5.51B | ¥6.16B |
| Intangible assets excluding goodwill | ¥458M | ¥353M | ¥278M | ¥265M | ¥295M |
| Investment securities | ¥3.22B | ¥4.08B | ¥4.39B | ¥3.86B | ¥4.31B |
| Current assets | ¥6.26B | ¥7.14B | ¥7.05B | ¥8.19B | ¥7.77B |
| Current liabilities | ¥2.13B | ¥2.82B | ¥3.23B | ¥2.84B | ¥2.58B |
| Trade payables | ¥983M | ¥1.38B | ¥1.34B | ¥1.29B | ¥814M |
| Short-term borrowings | — | — | — | — | ¥300M |
| Long-term borrowings | ¥469M | ¥242M | ¥106M | ¥1.26B | ¥1.21B |
| Total liabilities | ¥4.02B | ¥4.71B | ¥5.04B | ¥5.74B | ¥5.65B |
| Equity attributable to owners of parent | ¥9.22B | ¥9.56B | ¥10.1B | ¥10.5B | ¥10.9B |
| Retained earnings | ¥4.83B | ¥5.17B | ¥5.71B | ¥6.05B | ¥6.45B |
| Treasury stock | -¥120M | -¥114M | -¥108M | -¥99M | -¥86M |
EDINET (FSA Japan)
有価証券報告書－第89期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第88期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第87期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第86期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第85期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第84期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 48 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.